Get started
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsETFsBonds
Full chart
Full chart

Key facts today


Ionis (IONS) secured FDA approvals for TRYNGOLZA (sHTG) and ZANVASTRO (Alexander disease). A third regulatory decision from partner GSK on a chronic hepatitis B drug is expected in October. 1
Ionis (IONS) finished enrollment in its Phase III Angelman trial, plans H2 data release, noted a rival program’s poor results, and will publish longer-term Phase II HALOS dosing data. 1
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪7.39 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.5 USD
Net income (FY)
‪−381.39 M‬ USD
Revenue (FY)
‪943.71 M‬ USD
Shares float
‪162.92 M‬
Beta (1Y)
0.96

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪1.4 K‬
Change (1Y)
+333+31.15%
Revenue / Employee (1Y)
‪673.12 K‬ USD
Net income / Employee (1Y)
‪−272.03 K‬ USD

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Brett P. Monia
Website
ionis.com
Headquarters
Carlsbad
Founded
1989
IPO date
May 17, 1991
ISIN
US4622221004
CUSIP
462222100
FIGI
BBG00JVRNSN2
Identifiers
ISIN US4622221004
CFI code
ESVUFR
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


— YTM
Maturity dateJun 15, 2028
Coupon1.75% (Fixed)
— YTM
Maturity dateDec 1, 2030
Coupon0% (Zero)

See all 0JDI bonds 

ETFs holding the stock


VTI
Vanguard Morningstar Total Stock Market ETF
Weight0.01%
Market value‪301.79 M‬
VB
Vanguard Morningstar Small-Cap ETF
Weight0.12%
Market value‪218.08 M‬
VBK
Vanguard Morningstar Small-Cap Growth ETF
Weight0.27%
Market value‪125.17 M‬
VXF
Vanguard Extended Market ETF
Weight0.12%
Market value‪115.94 M‬
XBI
State Street SPDR S&P Biotech ETF
Weight0.61%
Market value‪64.60 M‬
CGGR
Capital Group Growth ETF
Weight0.25%
Market value‪62.57 M‬
IBB
iShares Biotechnology ETF
Weight0.53%
Market value‪55.17 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight0.17%
Market value‪42.37 M‬
IWP
iShares Russell Midcap Growth ETF
Weight0.20%
Market value‪38.85 M‬
ARKG
ARK Genomic Revolution ETF
Weight1.60%
Market value‪35.43 M‬
IWR
iShares Russell Mid-Cap ETF
Weight0.05%
Market value‪30.03 M‬

Explore more ETFs 

Frequently asked questions


The current price of 0JDI is 45.0 USD — it has decreased by −3.46% in the past 24 hours. Watch Ionis Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Ionis Pharmaceuticals, Inc. stocks are traded under the ticker 0JDI.
0JDI stock has fallen by −18.45% compared to the previous week, the month change is a −24.59% fall, over the last year Ionis Pharmaceuticals, Inc. has showed a −27.67% decrease.
We've gathered analysts' opinions on Ionis Pharmaceuticals, Inc. future price: according to them, 0JDI price has a max estimate of 105.00 USD and a min estimate of 54.00 USD. Watch 0JDI chart and read a more detailed Ionis Pharmaceuticals, Inc. stock forecast: see what analysts think of Ionis Pharmaceuticals, Inc. and suggest that you do with its stocks.
0JDI reached its all-time high on Jul 8, 2026 with the price of 86.7 USD, and its all-time low was 24.6 USD and was reached on Apr 9, 2025. View more price dynamics on 0JDI chart.
See other stocks reaching their highest and lowest prices.
0JDI stock is 6.34% volatile and has beta coefficient of 0.96. Track Ionis Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ionis Pharmaceuticals, Inc. there?
Today Ionis Pharmaceuticals, Inc. has the market capitalization of ‪7.39 B‬, it has decreased by −5.49% over the last week.
Yes, you can track Ionis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Ionis Pharmaceuticals, Inc. is going to release the next earnings report on Nov 4, 2026. Keep track of upcoming events with our Earnings Calendar.
0JDI earnings for the last quarter are −0.69 USD per share, whereas the estimation was −1.09 USD resulting in a 36.63% surprise. The estimated earnings for the next quarter are −1.21 USD per share. See more details about Ionis Pharmaceuticals, Inc. earnings.
Ionis Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪268.00 M‬ USD, despite the estimated figure of ‪189.10 M‬ USD. In the next quarter, revenue is expected to reach ‪181.81 M‬ USD.
0JDI net income for the last quarter is ‪−114.65 M‬ USD, while the quarter before that showed ‪−92.53 M‬ USD of net income which accounts for 0.00% change. Track more Ionis Pharmaceuticals, Inc. financial stats to get the full picture.
No, 0JDI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 20, 2026, the company has ‪1.4 K‬ employees. See our rating of the largest employees — is Ionis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ionis Pharmaceuticals, Inc. EBITDA is ‪−567.97 M‬ USD, and current EBITDA margin is −38.04%. See more stats in Ionis Pharmaceuticals, Inc. financial statements.
Like other stocks, 0JDI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ionis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ionis Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ionis Pharmaceuticals, Inc. stock shows the strong sell signal. See more of Ionis Pharmaceuticals, Inc. technicals for a more comprehensive analysis.